ORIC earnings

Rinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 global Phase 3 registrational trial in post-abiraterone mCRPC, with initiation expected in 1H 2026 At a median follow-up of ~5 months, landmark 5-month rPFS of 84% is consistent with competitor PRC2 inhibitor and substantially better than standard of care therapies in mCRPC Highly differentiated, potential best-in-disease safety profile, with significantly lower frequency and severity of adverse events, nearly all Grade 1 or 2, and far fewer treatment modifications than competitor regimens Company to host a conference call and webcast today at 4:30 pm ET SOUTH SAN FRANCISCO, Calif. and SAN D

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that it will report combination dose optimization data from the Phase 1b trial of rinzimetostat (ORIC-944) in patients with metastatic castration resistant prostate cancer (mCRPC) in a conference call and webcast on Tuesday, March 31, 2026 at 4:30pm ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call.

Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases 45% ORR in 2L patients exceeds competitor benchmarks Competitive safety profile, with no significant off-target toxicity and manageable on-target toxicity, resulting in low discontinuation rate Enrollment and follow-up continue in 1L patients at selected dose of 80 mg once daily, with next update expected mid-2026 ahead of initiation of potential Phase 3 trial Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- OR

Systemic activity of 35% ORR in 2L+ patients, including in patients with active brain metastases Manageable safety profile with low discontinuation rate Enrollment completed; no further development planned in this patient population Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025. Data in previously treated NSCLC pati

Highly differentiated 1L EGFR PACC preliminary systemic activity of 80% ORR and 100% intracranial ORR, including in patients with active brain metastases 36% ORR in median 3L EGFR PACC patients exceeds competitor benchmarks Competitive safety profile, with no significant off-target toxicity and manageable on-target toxicity, resulting in low discontinuation rate Enrollment and follow-up continue in 1L EGFR PACC patients at selected dose of 80 mg once daily, with next update expected mid-2026 ahead of initiation of potential Phase 3 trial Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 04, 2025 (GLOBE NE

SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced two late-breaking oral presentations highlighting data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025 taking place December 5-7, 2025 in Singapore. The mini-oral presentation will focus on data in previously treated patients with EGFR atypical mutant NSCLC, and the proffered paper oral presentation will focus on data in previously treated and treatment-naïve patients with EGFR exon 20 mutant NCSLC. Mini-oral presentat

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced a poster presentation highlighting data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025 taking place December 5-7, 2025 in Singapore. The poster will focus on data in previously treated patients with HER2 exon 20 mutant NSCLC. Poster presentation details:   Title:Enozertinib (ORIC-114), a Highly Selective, Brain Penetrant EGFR and HER2 Inhibitor, in Patients with HER2 Exon 20 Mutant NSCLC: Randomized Dose Optim

Broad and deep PSA responses achieved, with 59% PSA50 response rate (confirmed rate of 47%, and one additional response pending confirmation) and 24% PSA90 response rate (all confirmed) in patients with mCRPC       PSA responses were observed across all ORIC-944 dose levels and at comparable rates in combination with apalutamide and with darolutamide; majority of patients are still ongoing with multiple patients approaching one year or more Both combination regimens demonstrated a safety profile compatible with long term dosing, with the vast majority of adverse events Grade 1 or 2 Announced concurrent $125 million financing, which extends cash runway into 2H 2027 and through anticipated

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present initial data from the Phase 1b trial of ORIC-944 in combination with androgen receptor inhibitors in patients with metastatic castration resistant prostate cancer (mCRPC) in a conference call and webcast on Wednesday, May 28, 2025, at 4:30 p.m. ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode req

Preliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients Clean safety profile with only Grade 1 and 2 treatment related adverse events and no dose limiting toxicities or dose reductions Clinical activity, safety profile, and dose-dependent increases in immune cell activation support potential for combination studies with other multiple myeloma agents, including BCMA- and CD38-directed therapies Company to pursue strategic partnership for combination studies, resulting in extension of cash runway into 2026 Company to host conference call and webcast today at 4:30 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 11

CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient with documented untreated brain metastases Systemic responses observed at multiple dose levels in heavily pre-treated NSCLC patients, characterized by 81% having received prior EGFR exon 20 targeted agents and 86% having CNS metastases at baseline At potential RP2D of 75 mg QD, responses observed in 2 of 3 EGFR exon 20 patients previously treated with amivantamab (67% ORR), including a confirmed complete response Responses observed at multiple dose levels in HER2 exon 20 patients, including a partial response with 100% target lesion

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present two poster presentations at the European Society of Medical Oncology (ESMO) Congress 2023 taking place October 20-24, 2023, in Madrid, Spain. The presentations will highlight the initial Phase 1b clinical data for ORIC-114 in EGFR/HER2 exon 20 mutated cancers and new preclinical data for ORIC-114 demonstrating activity against additional atypical mutations in EGFR. In conjunction with the ESMO presentations, OR

Announces decision to discontinue development of ORIC-101 Company will focus on advancing its three single agent Phase 1 programs, ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer, with initial data expected from the three programs in 1H 2023 With cash and investments of $280.4 million, cash runway extended into 2H 2024 Conference call and webcast today at 5:00 p.m. ET SOUTH SAN FRANCISCO Calif. and SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the discontinuation of

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 17, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will host a conference call and webcast to discuss its fourth quarter and full year 2021 financial results and provide an operational update on Monday, March 21, 2022, at 5:00 p.m. ET. Webcast and Conference Call To participate in the conference call, please dial (833) 651-0991 (domestic) or (918) 922-6080 (international) and refer to conference ID 8637367. A live webcast and audio archive of the conference call will be a

CD73 inhibition overcomes immunosuppression and demonstrates activity in assays derived from relapsed or refractory multiple myeloma patients, offering the potential for single agent activity in the clinic Phase 1 trial of single agent ORIC-533, a highly potent, orally bioavailable small molecule inhibitor of CD73, expected to initiate in 4Q 2021 in patients with multiple myeloma Conference call and webcast today at 5:30 p.m. ET SOUTH SAN FRANCISCO and SAN DIEGO, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance presented preclinical dat

Call to discuss poster presentation on ORIC CD73 inhibitor in human ex vivo multiple myeloma systems presented at the American Society of Hematology (ASH) Annual Meeting Senior author Dr. Kenneth Anderson to discuss beneficial effects of ORIC CD73 inhibitor on restoring human antitumor immunity in multiple myeloma Webcast event scheduled for Monday, December 13, 2021, at 5:30 p.m. ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will host a conference call and webcas

ORIC-101 and enzalutamide combination regimen at the recommended Phase 2 dose was well tolerated; adverse events generally consistent with single agent enzalutamide ORIC-101 plasma concentrations provided excellent target coverage, consistent suppression of key glucocorticoid receptor (GR) biomarkers, and no evidence of drug-drug interaction impacting enzalutamide The addition of ORIC-101 after progression on single agent enzalutamide enabled continued enzalutamide treatment, with preliminary evidence of longer time on treatment demonstrated in a key patient population with tumors having moderate to high GR versus low GR expression ORIC-114 demonstrated compelling brain exposure and

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced three poster presentations at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics to be held October 7-10, 2021. Details of the poster presentations are as follows:  Title:Initial results from a Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic prostate cancer Poster #:P041    Title:Biomarker results supporting selectio